NYSEArca - Delayed Quote USD

Capital Group Short Duration Municipal Income ETF (CGSM)

26.23 -0.01 (-0.04%)
At close: October 11 at 3:59 PM EDT
Loading Chart for CGSM
DELL
  • Previous Close 26.24
  • Open 26.22
  • Bid --
  • Ask --
  • Day's Range 26.21 - 26.23
  • 52 Week Range 24.99 - 26.34
  • Volume 87,296
  • Avg. Volume 216,175
  • Net Assets 465.89M
  • NAV 26.17
  • PE Ratio (TTM) --
  • Yield 3.04%
  • YTD Daily Total Return 3.84%
  • Beta (5Y Monthly) 0.00
  • Expense Ratio (net) 0.25%

The fund will normally invest at least 80% of its assets in, or derive at least 80% of its income from, securities that are exempt from regular federal income tax. Such securities consist of municipal bonds, which are debt obligations that pay interest that is exempt from federal income taxation, with payments made from a wide variety of sources, including governmental revenue streams and private enterprises. The fund is non-diversified.

Capital Group

Fund Family

Muni National Short

Fund Category

465.89M

Net Assets

2023-09-26

Inception Date

Performance Overview: CGSM

View More

Trailing returns as of 10/11/2024. Category is Muni National Short.

YTD Return

CGSM
3.84%
Category
2.75%
 

1-Year Return

CGSM
7.92%
Category
5.91%
 

3-Year Return

CGSM
0.00%
Category
1.21%
 

People Also Watch

Related ETF News

View More

Research Reports: CGSM

View More
  • Pfizer's Diverse Portfolio of Drugs and Vaccines Supports a Wide Moat

    Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.

    Rating
    Price Target
     
  • What does Argus have to say about BB?

    BLACKBERRY LTD has an Investment Rating of SELL; a target price of $2.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of Low.

    Rating
    Price Target
     
  • Johnson & Johnson Earnings: Largely in Line as New Products Ready to Offset Stelara Biosimilars

    Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.

    Rating
    Price Target
     
  • New products and M&A drive 2024 growth

    Johnson & Johnson is a diversified global healthcare company that develops, manufactures and markets products in two business segments: Innovative Medicine (formerly Pharmaceuticals) and MedTech.

    Rating
    Price Target
     

Related Tickers